Global Clinical Trials Data

...Because free data should be free

2263 studies found for coronavirus
New Search | Refine Search | Download Results

Study Details

Participant Details

Identifiers

Dates

Status
Study
Enrolling by invitation
Condition: Acute Respiratory Tract Infection|Acute Respiratory Insufficiency|Pneumonia|Septic Shock|Hypoxemia
Interventions: Standard therapy recommended by the Ministry of Health of the Russian Federation., Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection, Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin inhalation, Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection combined with Dalargin inhalation
Phase: P3
Sponsor: Burnasyan Federal Medical Biophysical Center
Collaborators:
Brief Summary / Brief Description: The purpose of the study is to evaluate an effectiveness of the drug Dalargin for the prevention and treatment of severe pulmonary complications symptoms associated with severe and critical coronavirus infection cases (SARS COVID19, expanded as Severe acute respiratory syndrome Cоrona Virus Disease 2019 ). Test drug that will be administered to patients are: - Dalargin, solution for inhalation administration, - Dalargin, solution for intravenous and intramuscular administration.
Other IDs: NCT04346693, DAL-05-04-2020
Study Start: 04/08/2020
Primary Completion: 12/01/2020
First Received: 04/15/2020
Not yet recruiting
Condition: Pneumonia, Pneumocystis|Coronavirus
Interventions: Darunavir and Cobicistat
Phase: P3
Sponsor: Shanghai Public Health Clinical Center
Collaborators:
Brief Summary / Brief Description: The study aims to evaluate the efficacy and safety of darunavir and cobistastat in the treatment of pneumonia caused by the 2019 novel coronavirus
Other IDs: NCT04252274, DACO-nCoV
Study Start: 01/30/2020
Primary Completion: 08/31/2020
First Received: 02/03/2020
Not yet recruiting
Condition: Pneumonia, Pneumocystis|Coronavirus
Interventions: Hydroxychloroquine
Phase: P3
Sponsor: Shanghai Public Health Clinical Center
Collaborators:
Brief Summary / Brief Description: The study aims to evaluate the efficacy and safety of hydroxychloroquine in the treatment of pneumonia caused by the 2019 novel coronavirus
Other IDs: NCT04261517, HC-nCoV
Study Start: 02/06/2020
Primary Completion: 08/31/2020
First Received: 02/07/2020
Not yet recruiting
Condition: Coronavirus Infections|Respiratory Infection Virus
Interventions: methylprednisolone therapy, Standard care
Phase: P2/3
Sponsor: Peking Union Medical College Hospital
Collaborators: Zhongda Hospital, Zhongnan Hospital, Renmin Hospital of Wuhan University
Brief Summary / Brief Description: In this multi-center, randomized, control study, the investigators will evaluate the efficacy and safety of glucocorticoid in combination with standard care for 2019 novel coronavirus (2019-nCoV) patents with Severe acute respiratory failure.
Other IDs: NCT04244591, Glucocorticoid nCoV
Study Start: 01/26/2020
Primary Completion: 04/25/2020
First Received: 01/28/2020
Enrolling by invitation
Condition: Pneumonia, Viral|Respiratory Failure
Interventions: Mefloquine, Hydroxychloroquine, Mefloquine + azithromycin + / - tocilizumab, Hydroxychloroquine + azithromycin + / - tocilizumab
Phase: P2
Sponsor: Burnasyan Federal Medical Biophysical Center
Collaborators:
Brief Summary / Brief Description: Study of the effectiveness and safety of the drug Mefloquine, tablets 250 mg, produced by FSUE "SPC" Farmzaschita " FMBA of Russia (Russia), in comparison with the drug Hydroxychloroquine, tablets 200 mg, for the treatment of patients with coronavirus infection, in the "off-label" mode, to make a decision on the possibility of expanding the indications for use.
Other IDs: NCT04347031, FL-01/20
Study Start: 04/08/2020
Primary Completion: 08/01/2020
First Received: 04/15/2020
Recruiting
Condition: Novel Coronavirus Pneumonia (COVID-19)
Interventions: High dose group:routine treatment + MSc (2 x10^6 / kg / time);Low dose group:routine treatment + MSc (1x10^6 / kg / time);
Phase: N/A
Sponsor: the First Affiliated Hospital of Xinxiang Medical University
Collaborators:
Brief Summary / Brief Description: Evaluation of novel coronavirus pneumonia (MSC) in the treatment of severe new coronavirus pneumonia
Other IDs: ChiCTR2000030835, N/A
Study Start: 02/14/2020
Primary Completion: 02/14/2021
First Received: 02/14/2020
Not yet recruiting
Condition: Acute Kidney Injury|Corona Virus Infection
Interventions:
Phase: N/A
Sponsor: University of Giessen
Collaborators:
Brief Summary / Brief Description: Acute kidney injury (AKI) is reported to occur in 0.5-9% of severe acute respiratory distress coronavirus 2-positive patients and AKI has been identified as an independent risk factor for in-hospital mortality. The present study aims to investigate the incidence of renal outcome of in-hospital patients diagnosed with COVID-19.
Other IDs: NCT04353583, AZ 58/20
Study Start: 04/01/2020
Primary Completion: 07/01/2020
First Received: 04/20/2020
Recruiting
Condition: Novel Coronavirus Pneumonia (COVID-19)
Interventions: Phosphoric chloroquine:2 tablets phosphoric chloroquine BID, complicated with therapy recommended by New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5);Placebo:2 tablets placebo BID, complicated with therapy recommended by New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5);
Phase: N/A
Sponsor: The Sixth Affiliated Hospital of Guangzhou Medical University (Qingyuan People's Hospital)
Collaborators:
Brief Summary / Brief Description: Main purpose: To evaluate the efficacy of phosphoric chloroquine for novel coronavirus through clearance time of novel coronavirus. Secondary purpose: 1. To evaluate the efficacy of phosphoric chloroquine for mild/common patients with novel coronavirus(COVID-19) pneumonia through other secondary outcomes; 2. To evaluate the safety of phosphoric chloroquine for patients with novel coronavirus(COVID-19) .
Other IDs: ChiCTR2000030031, N/A
Study Start: 02/20/2020
Primary Completion: 03/20/2021
First Received: 02/20/2020
Not yet recruiting
Condition: Novel Coronavirus Pneumonia (COVID-19)
Interventions: Phosphoric chloroquine:2 tablets phosphoric chloroquine BID, complicated with therapy recommended by New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5);Placebo:2 tablets placebo BID, complicated with therapy recommended by New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5);
Phase: N/A
Sponsor: Jingzhou Central Hospital
Collaborators:
Brief Summary / Brief Description: Main purpose: To evaluate the efficacy of phosphoric chloroquine for novel coronavirus through clearance time of novel coronavirus. secondary purpose: 1. To evaluate the efficacy of phosphoric chloroquine for mild/common patients with novel coronavirus(COVID-19) pneumonia through other secondary outcomes; 2. To evaluate the safety of phosphoric chloroquine for patients with novel coronavirus(COVID-19) .
Other IDs: ChiCTR2000029837, N/A
Study Start: 02/17/2020
Primary Completion: 03/17/2020
First Received: 02/17/2020
Not yet recruiting
Condition: COVID|Corona Virus Infection
Interventions: Nitazoxanide, Ivermectin, Chloroquine, Azithromycin
Phase: P3
Sponsor: Tanta University
Collaborators:
Brief Summary / Brief Description: Azithromycin has been shown to have a clinical efficacy against severe acute respiratory syndrome coronavirus 2; ivermectin has also demonstrated a remarkable experimental efficacy with a potential to be used for Coronavirus disease 2019.
Other IDs: NCT04382846, tanta covid treatment
Study Start: 05/08/2020
Primary Completion: 12/01/2030
First Received: 05/11/2020
Studies Shown (1 to 10)